Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Common Equity (2023 - 2025)

Historic Common Equity for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to $32.1 million.

  • Profound Medical's Common Equity rose 463.9% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.1 million, marking a year-over-year increase of 463.9%. This contributed to the annual value of $60.4 million for FY2024, which is 9351.14% up from last year.
  • Profound Medical's Common Equity amounted to $32.1 million in Q3 2025, which was up 463.9% from $39.3 million recorded in Q2 2025.
  • Profound Medical's Common Equity's 5-year high stood at $48.7 billion during Q1 2023, with a 5-year trough of $30.7 million in Q3 2024.
  • Moreover, its 3-year median value for Common Equity was $39.3 million (2025), whereas its average is $4.5 billion.
  • Data for Profound Medical's Common Equity shows a peak YoY increase of 9351.14% (in 2024) and a maximum YoY decrease of 9990.66% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Profound Medical's Common Equity stood at $31.2 million in 2023, then surged by 93.51% to $60.4 million in 2024, then plummeted by 46.8% to $32.1 million in 2025.
  • Its Common Equity was $32.1 million in Q3 2025, compared to $39.3 million in Q2 2025 and $50.8 million in Q1 2025.